NCT00986232View on ClinicalTrials.gov

ProQuad Dose Selection Study (V221-011)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

1,551

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

April 30, 2000

Study Completion Date

September 30, 2000

Conditions
MeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live

a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90

BIOLOGICAL

Comparator: M-M-R II

A single 0.5 mL subcutaneous injection at Day 0

BIOLOGICAL

Comparator: PUVV

A single 0.5 mL subcutaneous injection at Day 0

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY